Fig. 4

H3K27me3 is established on Eed oocyte DEGs in primary–secondary mouse oocytes and is conserved in human GV oocytes a Venn diagram showing Eed oocyte DEGs that contained H3K27me3 promoter peaks in GV and MII oocyte H3K27me3 ChIP-seq data sets [44, 46] identifying 99 “high-confidence” H3K27me3-enriched Eed oocyte DEGs. b Heat map showing promoter H3K27me3 enrichment status of 99 high-confidence H3K27me3-enriched Eed oocyte DEGs identified in P7, P14, GV and MII oocyte H3K27me3 ChIP-seq data sets from Liu et al., and Zheng et al., [44, 46]. Blue: No H3K27me3 peaks, yellow: indicates presence of H3K27me3 peaks. c Expression fold change of the 99 high-confidence H3K27me3-enriched Eed oocyte DEGs (FDR < 0.05) in Eed-hom oocytes relative to Eed-het. The orange line indicates twofold change. d Donut chart showing the promoter H3K27me3 enrichment status of Eed oocyte DEGs in human GV oocytes [48]. Grey: Not conserved in humans, blue: no H3K27me3 peaks in promoter, yellow: H3K27me3 peak present in promoter. e Expression fold change of 132 mouse Eed oocyte DEGs (FDR < 0.05) that were H3K27me3-enriched in human GV oocytes. Eed oocyte DEGs commonly enriched for H3K27me3 in human and mouse GV oocytes are marked with gene names in red. The orange line indicates two-fold change. For a,b and d, promoter region was defined as 2000 bp upstream and downstream of TSS, overlap of > 200 bp H3K27me3 peaks with the promoter region was considered H3K27me3-enriched